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Introduction: Photodynamic therapy is a minimally invasive clinical treatment 
modality for a  variety of premalignant and malignant conditions combining 
a photosensitizing drug, oxygen and light irradiation. Hematoporphyrin is an 
organic photosensitizer, which mediates inhibition of endothelial cell prolifer-
ation and induces apoptosis. Human serum albumin is an endogenous drug 
carrier for hematoporphyrin. The present study aimed to investigate the hema-
toporphyrin binding to human serum albumin, which is its transport protein.
Material and methods: The chemical reagents were hematoporphyrin (Hp), 
human serum albumin (HSA) and bovine serum albumin (BSA). In the exper-
iment two techniques were used: spectrofluorimetry and UV-Vis absorption 
spectrophotometry.
Results: The binding sites for Hp were identified in the tertiary structure of 
HSA by fluorescence quenching technique. The experiment with BSA deliv-
ered additional data on Hp-albumin interactions close to Trp135. The par-
ticipation of tyrosyl residues apart from tryptophanyl ones was discussed. 
A  decrease of the polarity in the binding sites, testifying to possible hy-
drogen bonding in the binding sites, was also described. The binding and 
quenching constants Hp-HSA and Hp-BSA were determined as well as the 
number of binding sites.
Conclusions: Hp locates in subdomain IIA in the tertiary structure of HSA. 
The location in subdomain I close to Trp135 is also possible. Hp is also able 
to interact within tyrosyl residues.
Key words: photodynamic therapy, photosensitizer, human serum albumin, 
bovine serum albumin, photodynamic diagnosis, hematoporphyrin, 
emission fluorescence.
Introduction
Photodynamic therapy (PDT) is a minimally invasive clinical treatment 
modality for a variety of premalignant and malignant conditions [1, 2]. 
It combines a  photosensitizing drug, which selectively accumulates in 
tumor tissue and sensitizes it to light, oxygen (3O2) and laser light irradi-
ation to produce highly reactive singlet oxygen (1O2). It leads to destruc-
tion of cellular membranes and intracellular organelles, DNA damage 
and finally destruction of target cells [1, 3, 4]. 
PDT has been approved to treat patients with variety of early stages 
of precancerous lesions and cancers of lungs, esophagus (including Bar-
rett’s esophagus), rectum and colon, breast, skin, head and neck, urinary 
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bladder, female reproductive tract and pancreas 
[1–9]. PDT may also be applied in the palliative 
care of cancers in the above-mentioned locations. 
Another indication for PDT is the treatment of 
microbiological infections of burns, wounds and 
ulcers [3, 10]. 
Clinical outcomes of PDT may remain subopti-
mal, either insufficient or excessive, and depend 
on local photosensitizer concentration in the tar-
get tissue, local tissue oxygenation and local light 
fluence [1]. PDT has good tolerance and mild ad-
verse effects, minimizes the risk of complications, 
improves quality of life and should be considered 
as an effective alternative treatment [2, 3, 5, 6]. 
However, PDT is still not considered in some guide-
lines due to the large variety of PDT parameters, 
including photosensitizer concentration and dos-
age of light [3]. Knowledge of the mechanisms of 
absorption and distribution of photosensitizers 
allows maximal efficiency of the photodynamic re-
sponse to be achieved [11]. 
Porphyrins, which include hematoporphyrin 
(Hp), are the best-studied group of photosensitiz-
ers. Hp is an organic photosensitizer, which medi-
ates inhibition of endothelial cell proliferation in 
PDT and induces apoptosis [2, 4, 12–14]. Hp has 
good efficacy and a  low recurrence rate [14]. In 
accordance with the general rule of systemic in-
jection of a photosensitizer in PDT, Hp is adminis-
tered intravenously [6, 15]. 
Serum albumins (SA) constitute 55–65% of all 
serum proteins. Their physiological concentration 
of 40–50 g/l is a result of food supply, absorption, 
distribution between plasma and interstitial flu-
id as well as degradation. The human serum al-
bumin (HSA) molecule with a molecular mass of 
67000  Da consists of 585 amino acid residues 
forming one polypeptide chain, of which 67% 
form the α helical structure. The HSA polypeptide 
chain is formed in the shape of a  80 × 80 × 80 
× 30 Å heart [16–18]. The albumin molecule con-
tains three structurally homologous domains: I, II 
and III. Each of these domains is formed by two 
subdomains: A and B. Subdomains A and B con-
sist of 4 and 6 α helices, respectively [16–18]. Each 
subdomain A  is wider than subdomain B [19]. 
SAs of other species (e.g. bovine, horse, mouse, 
dog, salmon, frog) have a  repeating amino acid 
sequence [20]. Bovine serum albumin (BSA) has 
the most similar structure to HSA. The structure 
of HSA and BSA is 76% identical. The molecular 
weight of BSA is 66500 Da. The BSA amino acid 
sequence contains two tryptophans (Trps), Trp135 
and Trp214, while HSA contains Trp214 only [21]. 
One of the most important properties of al-
bumin is the ability to bind and transport many 
endo- and exogenous compounds lacking spe-
cific transport proteins. Endogenous compounds 
include fatty acids, bilirubin, uric acid, hormones, 
vitamins, and metal ions (Ca2+, Cu2+, Zn2+). Exoge-
nous ligands are primarily drugs (e.g. salicylates, 
sulfonamides, antibiotics) and contrast agents, 
including photosensitizers [22–25]. The complex 
formed between ligand and albumin protects the 
ligand against oxidation, reduces its toxicity, in-
creases its solubility in the serum and therefore 
improves its transport [26].
The present spectroscopic study aimed to in-
vestigate the binding of Hp to HSA, which is its 
transport protein, determine the loci of Hp bind-
ing in the tertiary structure of the albumin and 
study the interactions in Hp-HSA complexes. 
Material and methods
Chemical reagents
Hematoporphyrin, molecular weight 598.71 Da, 
was purchased from Sigma-Aldrich Inc. St. Louis, 
USA. Human serum albumin, fraction V, molecu-
lar weight 67000 Da, was obtained from ICN Bio-
medical Inc. Aurora, USA. Bovine serum albumin, 
molecular weight 66500  Da, was obtained from 
Biomed Lublin, Poland. 
Absorption spectra 
The absorption UV-Vis spectra were recorded 
with Jasco V-530 spectrometer (Jasco Internation-
al Co., Ltd., Tokyo, Japan). The UV-Vis spectra of 
HSA, BSA and Hp were recorded in the wavelength 
range 210-690 nm, 30 min after sample prepara-
tion, at 25°C. Correcting error of apparatus for the 
wavelength (λ) is ±1 nm, while for the absorbance 
(A) it is ±0.00001.
Fluorescence analysis 
The emission fluorescence spectra were record-
ed with Kontron SFM-25 Instrument AG (Kontron 
AG, Zurich, Switzerland) 30 min after preparation 
of the solutions, at 25°C. Correcting error of ap-
paratus for the wavelength (λ) is ±1 nm, while for 
the relative fluorescence (RF) it is ±0.01. 
To excite fluorophores two wavelengths were 
used: λ
ex = 280  nm and 295  nm. The emission 
spectra were recorded in the wavelength range 
280–400 nm and 295–400 nm for λ
ex = 280 nm 
and 295 nm, respectively. The concentration was 
adjusted to produce an absorbance (A ≤ 0.05) and 
the fluorescence spectra were not corrected for 
the inner filter effect [27]. 
The best solubility of Hp was obtained in phos-
phate buffer 0.05 M, pH 7.40. This buffer was used 
to prepare solutions of Hp and both SAs.
In the study of Hp binding to HAS and BSA the 
concentration range of Hp was 0 to 9 × 10–5 M and 
0 to 5 × 10–5 M, respectively. 
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For each BSA solution from 5 × 10–7 M to 1 × 
10–7 M the samples containing Hp within the con-
centration range from 0 to 5 × 10–5 M were pre-
pared. For each HSA solution from 2.5 × 10–6  M 
to 2.5 × 10–7 M the samples containing Hp within 
the concentration range from 0 to 9 × 10–5 M were 
prepared. 
The association constant (Ka) was determined by 
the Scatchard method modified by Hiratsuka [28]: 
= nK
a
 – K
a
r
r
L  (eq. 1)
where: r – fractional saturation of sites; r = ΔRF/
ΔRFmax (where: ΔRF = RF – RF0; ΔRFmax = RFmax – 
RF0); [L ] – free ligand concentration; Ka – asso-
ciation constant; n – number of binding sites for 
the independent class of ligand binding sites in 
the albumin molecule, which corresponds to the 
mean number of ligand molecules bound to the 
independent class of ligand binding sites in the 
albumin molecule. 
The fluorescence quenching effect and the 
Stern-Volmer constants were estimated based on 
the Stern-Volmer equation (eq.  2), which allows 
one to describe ligand movement within the fluo-
rophore microenvironment upon dynamic quench-
ing [29]:
= 1 + k
q
τ0[Q] = 1 + KQ[Q]
RF0
RF  
(eq. 2)
where: RF0 and RF – fluorescence intensities in the 
absence and presence of the quencher (Q), respec-
tively; k
q
 – rate quenching constant (M–1 s–1); τ0 – 
fluorescence lifetime in the absence of quencher; 
K
Q
 – quenching constant; [Q] – quencher (Hp) con-
centration. 
The Stern-Volmer equation modified by Lehrer 
[30] was used to determine the quenching con-
stant (K
Q
): 
= · · +
RF0
ΔRF
1
[Q]
1
a
1
a
1
K
Q
 
(eq. 3)
where: RF0 and RF – fluorescence intensities in 
the absence and presence of the quencher (Q), re-
spectively; ΔRF – difference between RF0 and RF; 
a – fractional accessible protein fluorescence; KQ 
– quenching constant; [Q] – quencher (Hp) con-
centration. 
Results and discussion
Quenching fluorescence study – complex 
formation
Spectrofluorimetry was used to study the com-
plex formation between Hp and both BSA and 
HSA. The emission fluorescence spectra of HSA 
Figure 1. Quenching of HSA fluorescence (at concentration 1.25 × 10–6 M) excited at λex = 280 nm (A) and λex = 
295 nm (B) in the presence of Hp within concentration range from 0 to 9 × 10–5 M (I – 0 M; II – 2 × 10–8 M; III – 5 × 
10–8 M; IV – 1 × 10–7 M; V – 5 × 10–7 M; VI – 1 × 10–6 M; VII – 1.5 × 10–6 M; VIII – 3.5 × 10–6 M; IX – 5 × 10–6 M; X – 7.5 
× 10–6 M; XI – 1 × 10–5 M; XII – 1.5 × 10–5 M; XIII – 2.5 × 10–5 M; XIV – 3 × 10–5 M; XV – 4 × 10–5 M; XVI – 5 × 10–5 M; 
XVII – 8 × 10–5 M; XVIII – 9 × 10–5 M)
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Figure 2. Quenching of BSA fluorescence (at concentration 4 × 10–7 M) excited at λex = 280 nm (A) and λex = 295 nm 
(B) in the presence of Hp within concentration range from 0 to 5 × 10–5 M (I – 0 M; II – 1 × 10–6 M; III – 1.5 × 10–6 M; 
IV – 2.5 × 10–6 M; V – 3.5 × 10–6 M; VI – 5 × 10–6 M; VII – 7.5 × 10–6 M; VIII – 1 × 10–5 M; IX – 1.25 × 10–5 M; X – 1.5 × 
10–5 M; XI – 2 × 10–5 M; XII – 2.5 × 10–5 M; XIII – 3 × 10–5 M; XIV – 4 × 10–5 M; XV – 5 × 10–5 M)
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excited at λex = 280 nm and 295 nm have signals 
at λmax = 334–336 nm and λmax = 343–345 nm, re-
spectively (Figures 1 A, B). The emission fluores-
cence spectra of BSA excited at λex = 280 nm and 
295  nm have signals at λmax = 333–339  nm and 
λmax = 326–333 nm, respectively (Figures 2 A, B). 
For the above presented solutions of SAs and 
Hp the fluorescence quenching curves, Stern-Vol-
mer curves and Scatchard curves have been plot-
ted and discussed below. 
Two binding sites for ligands were initially de-
scribed by Sudlow: the first was a “warfarin bind-
ing site”, while the second was the “benzodiaz-
epine binding site” [31]. Site I  is a  hydrophobic 
niche containing Trp214 (in both HSA and BSA 
molecules) and is located in subdomain IIA [32]. 
Site I is very flexible and presents high adaptabil-
ity to the ligand [33]. Site II can bind smaller or-
ganic molecules. The flexibility of site II is much 
lower [34].
The changes in HSA emission fluorescence 
upon binding Hp are shown in Figures 1 A and B 
for λex = 280 nm and 295 nm, respectively. A simi-
lar effect is observed for BSA (Figures 2 A and B for 
λex = 280 nm and 295 nm, respectively). 
The HSA fluorescence has been compared to 
its fluorescence quenched by Hp (Figures 1 A, B). 
Fluorescence of HSA excited at λex = 280  nm is 
quenched by Hp to 10.9%, 4.7% and 3.3% of its 
initial value at the Hp : HSA molar ratios 40 : 1, 
64 : 1 and 72 : 1, respectively (Figures 1 A, 3 A, 
4 A). Fluorescence of HSA excited at λex = 295 nm 
decreases to 10.8%, 8.4%, 5.2% and 3.3% of the 
initial value at Hp : HSA molar ratios 20 : 1, 24 : 1, 
32 : 1 and 40 : 1 for HSA concentration 4 × 10–7 M 
(Figures 1 B, 3 B, 4 A).
For molar ratios of Hp : BSA 62.5 : 1, 75 : 1, 
100 : 1 and 125 : 1 BSA fluorescence excited at λex 
= 280 nm reaches respectively 8.5%, 7.3%, 5.5% 
and 4.4% of the initial value for BSA concentration 
4 × 10–7  M (Figures  2 A, 3 A, 4 B). Fluorescence 
of BSA excited at λex = 295  nm is quenched to 
7.5%, 6.2%, 4.2% and 2.3% of the initial value for 
Hp : BSA molar ratios 62.5 : 1, 75 : 1, 100 : 1 and 
125 : 1 (Figures 2 B, 3 B, 4 B). 
The quenching of the fluorescence of both al-
bumins is positively correlated with Hp concen-
tration in the Hp-HSA and Hp-BSA solutions (Fig-
ures 1 and 2, respectively) and may be explained 
by the energy transfer from HSA and BSA fluo-
rophores to Hp chromophores [35]. This energy 
transfer may appear when the distance between 
fluorophores in the macromolecule of albumins 
and micromolecule of Hp does not exceed 10 nm, 
which is almost equal to the distance of van der 
Waals forces [36]. The experiment showed that 
fluorophores of Hp receive energy from excited 
HSA and BSA fluorophores. This phenomenon 
has been discussed by Eftink [36, 37] in the ex-
periment of energy transfer from indole excited at 
λex = 295 nm to acrylamide. In Eftink’s experiment 
the indole acts as a model of an albumin, because 
Figure 4. HSA (A) and BSA (B) fluorescence quenching curves by Hp for λex = 280 nm and λex = 295 nm
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Figure 3. HSA and BSA fluorescence quenching curves by Hp, λex = 280 nm (A) and λex = 295 nm (B)
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the tryptophanyl residues in the primary structure 
of albumin contain indole rings. 
To indicate the binding site of the Hp in the 
tertiary structure of the HSA the difference in the 
primary structure of both albumins (i.e. HSA and 
BSA) was taken into account. HSA contains one 
tryptophanyl group (Trp214) located in subdomain 
IIA, while BSA contains a second one (Trp135) in 
subdomain IB [19, 38]. Comparison of changes in 
fluorescence quenching of both albumins differ-
ing in the number of tryptophanyl groups allowed 
us to indicate the binding site of Hp in their struc-
ture.
Hp quenches fluorescence of HSA excited at 
λex = 280  nm less than BSA up to molar ratio 
Hp : SA 40 : 1 (Figure 3 A). For a higher molar ra-
tio HSA fluorescence is quenched more than that 
of BSA (Figure 3 A). An explanation of this differ-
ence may be the presence of two tryptophanyl 
groups (Trp135 and Trp214) in BSA and only one 
(Trp214) in HSA, apart from tyrosine (Tyr) groups 
excited at λex = 280  nm. Greater quenching of 
fluorescence of BSA containing two tryptophanyl 
groups (Trp135 and Trp214) indicates that the 
Hp molecules localize close to both Trps present 
in the BSA tertiary structure in subdomains IB 
and IIA. It can therefore be assumed that Hp has 
probably two binding sites in the tertiary struc-
ture of BSA and HSA, located in subdomains IB 
and IIA. In HSA fluorescence quenching is weak-
er, because HSA contains only Trp214 located in 
subdomain IIA. This means that spectroscopic 
information for HSA can only be obtained from 
subdomain IIA. For λex = 295  nm, HSA fluores-
cence is quenched more than that of BSA (Fig-
ure 3 B).
Interactions of Hp at the binding sites in 
the structure of HSA and BSA 
A  comparison between quenching of SA flu-
orescence excited at λex = 280 nm and 295 nm, 
causing excitation of both Tyrs and Trps and only 
Trps, respectively, gave information on the par-
ticipation of tyrosyl and tryptophanyl residues in 
the interactions in complexes of both albumins 
with Hp. 
Comparing the quenching of the BSA fluores-
cence excited at two wavelengths λex = 280  nm 
and λex = 295 nm by Hp (Figure 4 B), three rang-
es of Hp:BSA molar ratios were found. The over-
lapping quenching curves BSA-Hp might point 
to a  lack of interaction between Hp and tyrosyl 
residues in BSA for a molar ratio below 5 : 1 and 
over 25 : 1 (Figure 4 B). Higher quenching of BSA 
fluorescence excited at λ
ex = 280 nm than that at 
λex = 295 nm in the molar range Hp : BSA 5 : 1– 
25 : 1 points to the participation of tyrosyl groups 
in the interaction between Hp and BSA. 
The HSA fluorescence excited at λ
ex = 295 nm 
decreases in the presence of Hp more than that 
at λ
ex = 280  nm (Figure  4 A). Nearly complete 
(96.7%) quenching of HSA fluorescence at λex = 
280 nm by Hp occurs at a molar ratio Hp : HSA 
72 : 1, while at λ
ex = 295  nm a  similar effect 
was observed at a  molar ratio Hp : HSA 40 : 1. 
This suggests that the tertiary structure of BSA is 
altered in the presence of Hp and the binding sub-
domain changes its geometry when the complex 
with Hp forms. The change in the geometry of the 
binding site can be caused by the dimerization of 
Hp at concentrations exceeding 4 × 10–5 M, which 
was previously described by Silla et al. [39].
The decrease of HSA and BSA fluorescence by 
Hp at concentration 8 × 10–5 M is accompanied by 
a blue shift of the maximum fluorescence emis-
sion by 9 nm and 11 nm, respectively (Figures 1 B, 
2 B). Since the effect is observed at λ
ex = 295 nm 
the conclusions concern subdomains IB and IIA 
where Trp 135 and Trp214 are located. The ba-
thochromic shift of the maximum of albumin fluo-
rescence has been observed for albumin solutions 
in polar solvents [40]. Chadborn et al. explained 
the hypsochromic shift of the maximum fluores-
cence of Trp caused by different ligands by the 
increase in the hydrophobicity of the Trp environ-
ment [41]. The shift of the maximum of albumin 
fluorescence caused by Hp allowed assessment of 
the changes in the hydrophobic environment of 
the fluorophores of albumins. Hp can form hydro-
gen bonding not only with polar residues in the 
binding subdomain, but also with peptide bonds 
in SA. 
Table I. Association constants (K
a
), number of binding sites (n) and quenching constants (K
Q
) in the Hp complexes 
with HSA and BSA
HSA-Hp BSA-Hp
λex = 280 nm λex = 295 nm λex = 280 nm λex = 295 nm
K
a I = 9.31 × 10
5 M–1
n
I 
= 0.54
K
a II = 1.35 × 10
5 M–1
n
II 
= 1.0
K
a I = 5.37 × 10
6 M–1
n
I 
= 0.61
K
a II 
= 4.90 × 105 M–1
n
II = 1.1
K
a I = 3.77 × 10
6 M–1
n
I = 0.87
K
a II = 8.18 × 10
5 M–1
n
II = 1.1
K
a I = 2.43 × 10
6 M–1
n
I 
= 0.81
K
a II = 6.94 × 10
5 M–1
n
II = 1.1
K
Q = 2.52 × 10
6 M–1 K
Q = 2.08 × 10
5 M–1 K
Q = 2.01 × 10
6 M–1 K
Q = 6.35 × 10
5 M–1
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Association constants (Ka) and quenching 
constants (KQ) 
Eftink and Ghiron formulated a hypothesis that 
the increase in the number of sites occupied in the 
molecule decreases quenching of fluorescence 
[36, 37]. To verify this hypothesis the Stern-Volmer 
equations was analyzed. The quenching constant 
(K
Q
) was determined by the Stern-Volmer method 
modified by Lehrer (eq. 3) [30].
The Scatchard curve analysis gave information 
on the number of classes of binding sites for both 
Hp-BSA and Hp-HSA complexes. The strength of 
binding between the ligand and albumin was cal-
culated using the Scatchard method (eq. 1) [28]. 
The number of moles of ligands bound to one 
mole of albumin in the analyzed binding site was 
determined based on the Scatchard curves anal-
ysis.
To assess the stability and binding strength of 
Hp with HSA and BSA, the association constants 
(K
a
) and quenching constants (K
Q
) for both com-
plexes Hp-HSA and Hp-BSA were determined by 
analyzing the Scatchard (eq. 1) and Stern-Volmer 
equations (eq. 3) (Table I). The K
a
 values are rela-
tively high. They are of the order 105 and 106 (M–1). 
This may point to rather strong interaction be-
tween Hp and serum albumins. This confirms the 
suggestion that Hp may interact with the peptide 
bond in albumin by hydrogen bonding. 
The Scatchard curve analysis shows two classes 
of binding sites for both HSA and BSA (Table I). The K
a
 
for Hp binding with HSA and BSA was determined for 
λex = 280 nm and 295 nm for both classes of bind-
ing sites (Table I). 
There was lower for HSA (n
I = 0.54–0.61) and 
higher for BSA (n
I = 0.81–0.87) affinity of Hp in the 
first class of binding sites and the same (n
II 
= 1.0–
1.1) affinity in the second class (Table I). The high-
er number of Hp molecules in I class binding sites 
in BSA compared to HSA may be explained by the 
experiment that allowed us to observe different 
subdomains in BSA and HSA where Trps and Tyrs 
residues are located (i.e. IB, IIA and IIIA). The val-
ues of K
a
 indicate that between Hp and both albu-
mins the complexes are formed. Probably the π-π 
interactions are supported by hydrogen bonds, as 
indicated by the existence of two classes of bind-
ing sites. 
The comparison of K
a
 values for BSA and HSA 
shows that the binding of Hp to BSA is respective-
ly 3.1-fold higher than for HSA in the first class of 
binding sites for λex = 280 nm and 2.2-fold lower 
than HSA in the first class of binding sites for λex = 
295 nm. In the second class of binding sites bind-
ing of Hp to BSA is 6- and 1.4-fold higher than to 
HSA for λex = 280  nm and 295  nm, respectively. 
Larger K
Q
 values (for both HSA and BSA) were ob-
tained for λex = 280 nm than for λex = 295 nm. The 
difference may be a result of higher accessibility 
to fluorophores in the protein excited at 280 nm 
than 295 nm. 
In conclusion, the quenching of SA fluores-
cence by Hp points to the conclusion that Hp 
interacts with HSA in its subdomain IIA where 
Trp214 is located. The location in subdomain IA 
close to Trp135 is also possible. Hp is also able to 
interact within tyrosyl residues as demonstrated 
by the comparison of the quenching of SA fluores-
cence excited at 280 nm and 295 nm. 
Two classes of binding sites for Hp with dif-
ferent affinity towards HSA were identified. The 
Hp-HSA complex is stabilized by both hydropho-
bic interactions and hydrogen bonds between Hp 
and HSA. The BSA study enabled observation of 
interactions with Hp within subdomain IB of the 
albumin. 
A  decrease of the polarity around the fluoro-
phores in the binding site results from the pos-
sible hydrogen bonding between Hp and peptide 
bonds in SA. This is confirmed by the values of 
binding constants K
a
 being of the order 105 and 
106 (M–1). 
The obtained data on formation of the Hp-HSA 
complex, location of the Hp molecule in the tertia-
ry structure of the HSA molecule, and the nature 
of interactions between Hp and HSA are crucial for 
understanding transportation of Hp to the cancer 
tissue. However, future clinical trials are needed. 
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